Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments-Reference-Cited by-同舟云学术

Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments

Published:2024-04-01 Issue:5 Volume:42 Page:487-506
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Chang Jen-Yu Amy^ORCID,Chilcott James B.^ORCID,Latimer Nicholas R.^ORCID

Funder

Wellcome Trust

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40273-024-01363-1.pdf

Reference123 articles.

1. NICE. Position statement: consideration of products recommended for use in the Cancer Drugs Fund as comparators, or in a treatment sequence, in the appraisal of a new cancer product. Available at: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisal-guidance/cancer-drugs-fund/CDF-comparator-position-statement.pdf. Accessed 23 Mar 2020.

2. Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics. 2008;26:781–98.

3. Tosh J, Stevenson M, Akehurst R. Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review. Curr Rheumatol Rep. 2014;16:447.

4. Benedict A, Stevenson M, Sorensen S. ISPOR Europe 2017: Modeling separate lines of treatment versus treatment sequences in cancer (Workshop 8). Available at: https://www.ispor.org/docs/default-source/presentations/1221.pdf?sfvrsn=6f1f29a1_1. Accessed 20 June 2020.

5. Al M, Jin H, Robins J, et al. Virtual ISPOR Europe 2020: novel methods for modeling treatment sequencing (spotlight session 3). Available at: https://www.ispor.org/conferences-education/conferences/past-conferences/ispor-europe-2020/program/spotlight-sessions. Accessed 19 Nov 2020.